Patients with obsessive-compulsive disorder have increased 5-HT2A receptor binding in the caudate nuclei.

The pharmacological efficacy of serotonergic-acting drugs suggest that patients with obsessive-compulsive disorder (OCD) may have alterations in their cerebral serotonergic (5-HT) receptor system, and previous neuroimaging studies of OCD patients have shown abnormalities in several fronto-subcortical regions. In this study we investigated cerebral 5-HT(2A) receptor binding in 15 untreated OCD patients and in 15 age- and gender-matched healthy volunteers by magnetic resonance imaging and [(18)F]altanserin positron emission tomography (PET). Eleven of the patients were rescanned with PET after receiving treatment with a selective serotonin reuptake inhibitor (SSRI). The distribution volumes of specific tracer binding (DV(3)') were calculated for 12 brain regions, and comparisons were made between: (1) healthy volunteers vs. untreated OCD patients, (2) healthy volunteers vs. treated OCD patients, and (3) OCD patients before and during treatment. When comparing the distribution volume for specific fronto-subcortical brain regions, significantly higher values were recorded in the caudate nuclei in OCD patients (DV(3)': 0.24+/-0.14) compared to the healthy control group (DV(3)': 0.15+/-0.13) (p<0.05, Wilcoxon matched-pairs test). This difference between groups was not present after treatment with SSRIs. There was no correlation between the severity of OCD symptoms and 5-HT(2A )receptor binding. An increase in 5-HT(2A) receptor binding is found in the caudate nuclei of untreated patients with OCD. The up-regulation in 5-HT(2A) receptors might be compensatory for a lack of serotonin in the feedback loop between the thalamus and orbito-frontal cortex, the caudate nuclei, and the globus pallidus.

[1]  E. Hollander,et al.  Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers. , 1992, Archives of general psychiatry.

[2]  Søren Holm,et al.  [18F]altanserin Binding to Human 5HT2A Receptors is Unaltered after Citalopram and Pindolol Challenge , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[3]  B. Mazoyer,et al.  The cortical serotonin2 receptors studied with positron-emission tomography and [18F]-setoperone during depressive illness and antidepressant treatment with clomipramine , 1999, Biological Psychiatry.

[4]  P. Delgado,et al.  Hallucinogens, serotonin and obsessive-compulsive disorder. , 1998, Journal of psychoactive drugs.

[5]  Donald Sashin,et al.  Test–retest variability of serotonin 5‐HT2A receptor binding measured with positron emission tomography and [18F]altanserin in the human brain , 1998, Synapse.

[6]  Abraham Z Snyder,et al.  Greater loss of 5-HT(2A) receptors in midlife than in late life. , 2002, The American journal of psychiatry.

[7]  F Fazio,et al.  [18F]FDG PET Study in Obsessive–Compulsive Disorder , 1995, British Journal of Psychiatry.

[8]  G. Andrews,et al.  Controlled trial of exposure and response prevention in obsessive–compulsive disorder , 1997, British Journal of Psychiatry.

[9]  S. Hyman,et al.  A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory. , 1990, The American journal of psychiatry.

[10]  Sung-Cheng Huang,et al.  Differential cerebral metabolic changes with paroxetine treatment of obsessive-compulsive disorder vs major depression. , 2002, Archives of general psychiatry.

[11]  K. Hanes.  Serotonin, psilocybin, and body dysmorphic disorder: a case report. , 1996, Journal of clinical psychopharmacology.

[12]  Chester A. Mathis,et al.  Effects of estradiol and progesterone administration on human serotonin 2A receptor binding: a PET study , 2000, Biological Psychiatry.

[13]  D. Murphy,et al.  A comparison of the behavioral effects of oral versus intravenous mCPP administration in OCD patients and the effect of metergoline prior to IV mCPP , 1993, Biological Psychiatry.

[14]  M. Palkovits,et al.  5-HT uptake sites and 5-HT2 receptors in brain of antidepressant-free suicide victims/depressives: increase in 5-HT2 sites in cortex and amygdala , 1993, Brain Research.

[15]  J. Zohar,et al.  Paroxetine versus Clomipramine in the Treatment of Obsessive–Compulsive Disorder , 1996, British Journal of Psychiatry.

[16]  D. Murphy,et al.  Local cerebral glucose metabolic rates in obsessive-compulsive disorder. Patients treated with clomipramine. , 1990, Archives of general psychiatry.

[17]  Claus Svarer,et al.  Quantification of 5-HT2A Receptors in the Human Brain Using [18F]Altanserin-PET and the Bolus/Infusion Approach , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[18]  I. Law,et al.  The caudate nucleus in obsessive-compulsive disorder. Reduced metabolism following treatment with paroxetine: a PET study. , 2002, The international journal of neuropsychopharmacology.

[19]  V. Arango,et al.  Postmortem Findings in Suicide Victims. Implications for in Vivo Imaging Studies a , 1997, Annals of the New York Academy of Sciences.

[20]  H. Anisman,et al.  Obsessive-Compulsive Spectrum Disorders: Effective Treatment with Paroxetine , 1999, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[21]  S. Sorenson,et al.  The epidemiology of obsessive-compulsive disorder in five US communities. , 1988, Archives of general psychiatry.

[22]  C D Frith,et al.  Functional Anatomy of Obsessive–Compulsive Phenomena , 1994, British Journal of Psychiatry.

[23]  C. Lemaire,et al.  Fluorine-18-altanserin: a radioligand for the study of serotonin receptors with PET: radiolabeling and in vivo biologic behavior in rats. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  J. Mazziotta,et al.  Local cerebral glucose metabolic rates in obsessive-compulsive disorder. A comparison with rates in unipolar depression and in normal controls. , 1987, Archives of general psychiatry.

[25]  J. Leckman,et al.  The inheritance of Gilles de la Tourette's syndrome and associated behaviors. Evidence for autosomal dominant transmission. , 1986, The New England journal of medicine.

[26]  D. Charney,et al.  Characterization of radioactive metabolites of 5-HT2A receptor PET ligand [18F]altanserin in human and rodent. , 1999, Nuclear medicine and biology.

[27]  Alan A. Wilson,et al.  The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study. , 2001, The American journal of psychiatry.

[28]  W. Goodman,et al.  The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. , 1989, Archives of general psychiatry.

[29]  Charles F. Reynolds,et al.  Reduced binding of [ 18 F ]altanserin to serotonin type 2A receptors in aging: persistence of effect after partial volume correction , 1998, Brain Research.

[30]  J. Mazziotta,et al.  Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. , 1992, Archives of general psychiatry.

[31]  T G Turkington,et al.  Performance characteristics of a whole-body PET scanner. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[32]  Thomas K. Lewellen,et al.  Investigation of the performance of the General Electric Advance positron emission tomograph in 3D mode , 1995 .

[33]  J. Rapoport,et al.  Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. , 1989, Archives of general psychiatry.

[34]  P Pietrini,et al.  Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. Revisualization during pharmacotherapy. , 1992, Archives of general psychiatry.

[35]  M E Phelps,et al.  Systematic changes in cerebral glucose metabolic rate after successful behavior modification treatment of obsessive-compulsive disorder. , 1996, Archives of general psychiatry.

[36]  Paul J. Harrison,et al.  Expression of serotonin 5‐HT2A receptors in the human cerebellum and alterations in schizophrenia , 2001, Synapse.

[37]  P. Delgado,et al.  Hallucinogen-induced relief of obsessions and compulsions. , 1997, The American journal of psychiatry.

[38]  J. Dartigues,et al.  A Randomized Controlled Trial of Cognitive Therapy versus Intensive Behavior Therapy in Obsessive Compulsive Disorder , 2001, Psychotherapy and Psychosomatics.

[39]  T. Insel,et al.  Toward a neuroanatomy of obsessive-compulsive disorder. , 1992, Archives of general psychiatry.

[40]  D. Cohen,et al.  Gilles de la Tourette's syndrome and obsessive-compulsive disorder. Evidence supporting a genetic relationship. , 1986, Archives of general psychiatry.

[41]  J. Mazziotta,et al.  Cerebral glucose metabolic rates in nondepressed patients with obsessive-compulsive disorder. , 1988, The American journal of psychiatry.

[42]  H. Meltzer,et al.  Serotonergic measures in the brains of suicide victims: 5-HT2 binding sites in the frontal cortex of suicide victims and control subjects. , 1989, The American journal of psychiatry.

[43]  Sung-Cheng Huang,et al.  Cerebral metabolism in major depression and obsessive-compulsive disorder occurring separately and concurrently , 2001, Biological Psychiatry.

[44]  M. Weissman,et al.  The cross national epidemiology of obsessive compulsive disorder. The Cross National Collaborative Group. , 1994, The Journal of clinical psychiatry.

[45]  Patrick Dupont,et al.  Visualisation of loss of 5-HT2A receptors with age in healthy volunteers using [18F]altanserin and positron emission tomographic imaging , 1996, Psychiatry Research: Neuroimaging.

[46]  N. Lassen,et al.  Neuroreceptor Quantitation in vivo by the Steady-State Principle Using Constant Infusion or Bolus Injection of Radioactive Tracers , 1992, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[47]  S. Alborzian,et al.  Localized Orbitofrontal and Subcortical Metabolic Changes and Predictors of Response to Paroxetine Treatment in Obsessive-Compulsive Disorder , 1999, Neuropsychopharmacology.

[48]  Serge Goldman,et al.  Sex difference in 5HT2 receptor in the living human brain , 1996, Neuroscience Letters.

[49]  N. Alpert,et al.  Regional cerebral blood flow measured during symptom provocation in obsessive-compulsive disorder using oxygen 15-labeled carbon dioxide and positron emission tomography. , 1994, Archives of general psychiatry.

[50]  M. Jenike,et al.  Sertraline in obsessive-compulsive disorder: a double-blind comparison with placebo. , 1990, The American journal of psychiatry.